{"id":72351,"date":"2026-08-12T11:55:44","date_gmt":"2026-08-12T03:55:44","guid":{"rendered":"https:\/\/flcube.com\/?p=72351"},"modified":"2026-08-12T11:59:41","modified_gmt":"2026-08-12T03:59:41","slug":"mabwell-signs-licensing-deals-with-southeast-asia-partners-for-aflibercept-biosimilar-9mw0813-in-philippines-vietnam-and-malaysia","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72351","title":{"rendered":"Mabwell Signs Licensing Deals With Southeast Asia Partners for Aflibercept Biosimilar 9MW0813 in Philippines, Vietnam, and Malaysia"},"content":{"rendered":"\n

Mabwell<\/strong> (Shanghai) Bioscience Co., Ltd.<\/strong> (SHA: 688062<\/a>, HKG: 2493<\/a>) announced that it has entered into licensing agreements<\/strong> with local partners in the Philippines, Vietnam, and Malaysia<\/strong> for 9MW0813 (aflibercept)<\/strong>. Under the agreements, Mabwell will work with its partners to advance the product’s registration and commercialization<\/strong> in these countries.<\/p>\n\n\n\n

Deal Overview<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Mabwell (Shanghai) Bioscience Co., Ltd. (HKG: 2493)<\/td><\/tr>
Agreement Type<\/strong><\/td>Licensing agreements with local partners<\/td><\/tr>
Product<\/strong><\/td>9MW0813, a biosimilar candidate referencing aflibercept (EYLEA)<\/td><\/tr>
Territories<\/strong><\/td>Philippines, Vietnam, Malaysia<\/td><\/tr>
Announcement Date<\/strong><\/td>12 Aug 2026<\/td><\/tr>
Next Steps<\/strong><\/td>Registration and commercialization in the three markets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Profile<\/h2>\n\n\n\n